Preclinical testing of new drugs for tuberculosis: current challenges.
The continuing global epidemic of tuberculosis, the increasing rate of multidrug resistant (MDR) tuberculosis and the more recent emergence of extensively drug resistant (XDR) tuberculosis are great causes for concern. A major international effort is currently underway to optimize current drug therapies and to discover new drugs that are active against these organisms. This effort has created a pipeline of new candidate drugs at various stages of preclinical and early clinical evaluations. Major challenges still exist, however, varying from the standardization and application of current animal models and their application to drug discovery and characterization to the fact that our knowledge about the basic biology of the MDR and XDR strains of Mycobacterium tuberculosis is minimal at best.
Lenaerts
Anne J
AJ
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
Degroote
Mary Ann
MA
Orme
Ian M
IM
D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006168:Guinea Pigs; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000473:pathology; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D051381:Rats; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy
D000995:Antitubercular Agents